Pakistan vs Togo: HIV/AIDS deaths averted by antiretroviral therapy
Pakistan
4,811 deaths
in 2024
Togo
5,494 deaths
in 2024
Pakistan rank
38th
Togo rank
35th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Pakistan
- Togo
How they compare
Togo currently reports 5,494 deaths against 4,811 deaths in Pakistan, a difference of 683 deaths.
That makes Togo's figure about 1.1 times Pakistan's.
Across all 35 years both countries report, Togo has been ahead every year.
Pakistan ranks 38th and Togo ranks 35th of 157 countries.
Togo has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Pakistan | Togo | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 49.67 deaths | 940.75 deaths | 891.08 deaths | Togo |
| 2010s | 854.17 deaths | 4,416 deaths | 3,562 deaths | Togo |
| 2020s | 3,244 deaths | 5,603 deaths | 2,359 deaths | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Pakistan or Togo?
- Togo, at 5,494 deaths against 4,811 deaths in Pakistan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Pakistan and Togo?
- 683 deaths, with Togo ahead.
- How many years of comparable data are there for Pakistan and Togo?
- 35 years are reported by both, from 1990 to 2024.
- How do Pakistan and Togo rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Pakistan ranks 38th and Togo ranks 35th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.